Abstract
Endothelin-1 exerts vasoactive, pro-inflammatory, hypertrophic, and profibrotic properties on the heart, kidney, and blood vessels. Hence, endothelin-receptor antagonists hold the potential to reduce blood pressure and to prevent complications of hypertension, atherosclerosis, and diabetes through blood pressure-independent effects on cardiovascular growth, inflammation, and fibrosis. These potentially important effects of endothelin antagonism may contribute to its therapeutic potential in hypertension and other cardiovascular disorders, including chronic renal failure and diabetes. First clinical trial evidence demonstrates a moderate reduction in blood pressure in studies of patients with mild-to-moderate essential hypertension and patients with resistant hypertension. Future large-scale randomized clinical trials will provide more insight into whether the blood-pressure reduction and promising pleiotropic effects observed with several members of this novel class of drugs, which are already established therapy in pulmonary hypertension, will translate into clinical benefit in patients with arterial hypertension.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Yanagisawa M, Kurihara H, Kimura S, et al.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:411–415.
Malek A, Izumo S: Physiological fluid shear stress causes downregulation of endothelin-1 mRNA in bovine aortic endothelium. Am J Physiol 1992, 263(2 Pt 1):C389–396.
Boulanger C, Luscher TF: Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest 1990, 85:587–590.
Schiffrin EL: Vascular endothelin in hypertension. Vascul Pharmacol 2005, 43:19–29.
Quehenberger P, Exner M, Sunder-Plassmann R, et al.: Leptin induces endothelin-1 in endothelial cells in vitro. Circ Res 2002, 90:711–718.
Davenport AP, O’Reilly G, Kuc RE: Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type. Br J Pharmacol 1995, 114:1110–1116.
Bacon CR, Cary NR, Davenport AP: Endothelin peptide and receptors in human atherosclerotic coronary artery and aorta. Circ Res 1996, 79:794–801.
Goddard J, Eckhart C, Johnston NR, et al.: Endothelin A receptor antagonism and angiotensin-converting enzyme inhibition are synergistic via an endothelin B receptor-mediated and nitric oxide-dependent mechanism. J Am Soc Nephrol 2004, 15:2601–2610.
Haynes WG, Webb DJ: Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 1998, 16:1081–1098.
Fryer RM, Rakestraw PA, Banfor PN, et al.: Blood pressure regulation by ETA and ETB receptors in conscious, telemetry-instrumented mice and role of ETA in hypertension produced by selective ETB blockade. Am J Physiol Heart Circ Physiol 2006, 290:H2554–2559.
Li JS, Lariviere R, Schiffrin EL: Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycor-ticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy. Hypertension 1994, 24:183–188.
Schiffrin EL, Lariviere R, Li JS, et al.: Deoxycorticosterone acetate plus salt induces overexpression of vascular endothelin-1 and severe vascular hypertrophy in spontaneously hypertensive rats. Hypertension 1995, 25(4 Pt 2):769–773.
Doucet J, Gonzalez W, Michel JB: Endothelin antagonists in salt-dependent hypertension associated with renal insufficiency. J Cardiovasc Pharmacol 1996, 27:643–651.
Moreau P, d’Uscio LV, Shaw S, et al.: Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation 1997, 96:1593–1597.
Bergstrom G, Nystrom HC, Jia J, Evans RG: Effects of the ET(A)/ET(B) antagonist, TAK-044, on blood pressure and renal excretory function after unclipping of conscious one-kidney-one-clip hypertensive rats. J Hypertens 2001, 19(3 Pt 2):659–665.
Deng LY, Schiffrin EL: Endothelin-1 gene expression in blood vessels and kidney of spontaneously hypertensive rats (SHR), L-NAME-treated SHR, and renovascular hypertensive rats. J Cardiovasc Pharmacol 1998, 31(Suppl 1):S380–383.
Verma S, Bhanot S, McNeill JH: Effect of chronic endothelin blockade in hyperinsulinemic hypertensive rats. Am J Physiol 1995, 269(6 Pt 2):H2017–2021.
Schiffrin EL: Endothelin: role in experimental hypertension. J Cardiovasc Pharmacol 2000, 35(4 Suppl 2):S33–35.
Li JS, Schurch W, Schiffrin EL: Renal and vascular effects of chronic endothelin receptor antagonism in malignant hypertensive rats. Am J Hypertens 1996, 9:803–811.
Karam H, Heudes D, Bruneval P, et al.: Endothelin antagonism in end-organ damage of spontaneously hypertensive rats. Comparison with angiotensin-converting enzyme inhibition and calcium antagonism. Hypertension 1996, 28:379–385.
Barton M, Vos I, Shaw S, et al.: Dysfunctional renal nitric oxide synthase as a determinant of salt-sensitive hypertension: mechanisms of renal artery endothelial dysfunction and role of endothelin for vascular hypertrophy and glomerulosclerosis. J Am Soc Nephrol 2000, 11:835–845.
Taddei S, Virdis A, Ghiadoni L, et al.: Role of endothelin in the control of peripheral vascular tone in human hypertension. Heart Fail Rev 2001, 6:277–285.
Ergul S, Parish DC, Puett D, Ergul A: Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension 1996, 28:652–655.
Laffer CL, Bolterman RJ, Romero JC, Elijovich F: Effect of salt on isoprostanes in salt-sensitive essential hypertension. Hypertension 2006, 47:434–440.
Hirai Y, Adachi H, Fujiura Y, et al.: Plasma endothelin-1 level is related to renal function and smoking status but not to blood pressure: an epidemiological study. J Hypertens 2004, 22(4):713–718.
Haynes WG, Hand MF, Johnstone HA, et al.: Direct and sympathetically mediated venoconstriction in essential hypertension. Enhanced responses to endothelin-1. J Clin Invest 1994, 94:1359–1364.
Schiffrin EL, Deng LY, Larochelle P: Blunted effects of endothelin upon small subcutaneous resistance arteries of mild essential hypertensive patients. J Hypertens 1992, 10:437–444.
Cardillo C, Kilcoyne CM, Cannon RO 3rd, Panza JA: Interactions between nitric oxide and endothelin in the regulation of vascular tone of human resistance vessels in vivo. Hypertension 2000, 35:1237–1241.
Cardillo C, Kilcoyne CM, Waclawiw M, et al.: Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension 1999, 33:753–758.
Cardillo C, Campia U, Kilcoyne CM, et al.: Improved endothelium-dependent vasodilation after blockade of endothelin receptors in patients with essential hypertension. Circulation 2002, 105:452–456.
Verhaar MC, Strachan FE, Newby DE, et al.: Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998, 97:752–756.
Campia U, Cardillo C, Panza JA: Ethnic differences in the vasoconstrictor activity of endogenous endothelin-1 in hypertensive patients. Circulation 2004, 109:3191–3195.
Bohm F, Ahlborg G, Pernow J: Endothelin-1 inhibits endothelium-dependent vasodilatation in the human forearm: reversal by ETA receptor blockade in patients with atherosclerosis. Clin Sci (Lond) 2002, 102:321–327.
Taddei S, Virdis A, Ghiadoni L, et al.: Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension. Circulation 1999, 100:1680–1683.
Haynes WG, Ferro CJ, O’Kane KP, et al.: Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 1996, 93:1860–1870.
Spieker LE, Hurlimann D, Ruschitzka F, et al.: Mental stress induces prolonged endothelial dysfunction via endothelin-A receptors. Circulation 2002, 105:2817–2820.
Bayerle-Eder M, Langenberger H, Pleiner J, et al.: Endothelin ETA receptor-subtype specific antagonism does not mitigate the acute systemic or renal effects of exogenous angiotensin II in humans. Eur J Clin Invest 2002, 32:230–235.
Montanari A, Biggi A, Carra N, et al.: Endothelin-A receptors mediate renal hemodynamic effects of exogenous Angiotensin II in humans. Hypertension 2003, 42:825–830.
Schiffrin EL: The angiotensin-endothelin relationship: does it play a role in cardiovascular and renal pathophysiology?. J Hypertens 2003, 21:2245–2247.
Krum H, Viskoper RJ, Lacourciere Y, et al.: The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med 1998, 338:784–790.
Calhoun D, Renfoe K, Alper A: Oral sitaxsentan, an endothelin-A selective receptor antagonist, reduces systemic blood pressure in patients with mild-to-moderate primary hypertension. Circulation 2000, 102:417.
Nakov R, Pfarr E, Eberle S: Darusentan: an effective endothelin A receptor antagonist for treatment of hypertension. Am J Hypertens 2002, 15(7 Pt 1):583–589.
Battistini B, Berthiaume N, Kelland NF, et al.: Profile of past and current clinical trials involving endothelin receptor antagonists: the novel “-sentan” class of drug. Exp Biol Med (Maywood) 2006, 231:653–695.
Spieker LE, Mitrovic V, Noll G, et al.: Acute hemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure. ET 003 Investigators. J Am Coll Cardiol 2000, 35:1745–1752.
Anand I, McMurray J, Cohn JN, et al.: Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 2004, 364:347–354.
Luscher TF, Enseleit F, Pacher R, et al.: Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation 2002, 106:2666–2672.
Elijovich F, Laffer CL, Amador E, et al.: Regulation of plasma endothelin by salt in salt-sensitive hypertension. Circulation 2001, 103:263–268.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981–2997.
Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995–1003.
Kaplan NM: Resistant hypertension. J Hypertens 2005, 23:1441–1444.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sudano, I., Hermann, M. & Ruschitzka, F.T. Endothelin-receptor antagonists in arterial hypertension: Further indications?. Current Science Inc 9, 59–65 (2007). https://doi.org/10.1007/s11906-007-0011-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11906-007-0011-9